Milind Javle

22.2k total citations · 6 hit papers
399 papers, 11.9k citations indexed

About

Milind Javle is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Milind Javle has authored 399 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 260 papers in Oncology, 231 papers in Surgery and 122 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Milind Javle's work include Cholangiocarcinoma and Gallbladder Cancer Studies (199 papers), Pancreatic and Hepatic Oncology Research (119 papers) and Cancer Genomics and Diagnostics (75 papers). Milind Javle is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (199 papers), Pancreatic and Hepatic Oncology Research (119 papers) and Cancer Genomics and Diagnostics (75 papers). Milind Javle collaborates with scholars based in United States, United Kingdom and Spain. Milind Javle's co-authors include Rachna T. Shroff, Robert A. Wolff, Ahmed O. Kaseb, Nicola J. Curtin, Gauri R. Varadhachary, Mitesh J. Borad, Apurva Jain, Christopher H. Crane, Funda Meric‐Bernstam and James L. Abbruzzese and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Milind Javle

373 papers receiving 11.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

2019 321 citations Rachna T. Shroff, Milind Javle et al. profile →
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

2020 314 citations Vivek Subbiah, Milind Javle et al. profile →
Gallbladder Cancer: expert consensus statement

2015 297 citations Thomas A. Aloia, Milind Javle et al. profile →
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Milind Javle, Nilofer S. Azad et al. profile →
Gallbladder cancer

2022 174 citations Milind Javle et al. profile →
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Milind Javle

Since Specialization

Citations

This map shows the geographic impact of Milind Javle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milind Javle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milind Javle more than expected).

Fields of papers citing papers by Milind Javle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milind Javle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milind Javle. The network helps show where Milind Javle may publish in the future.

Co-authorship network of co-authors of Milind Javle

This figure shows the co-authorship network connecting the top 25 collaborators of Milind Javle. A scholar is included among the top collaborators of Milind Javle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milind Javle. Milind Javle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss 2024 ·Sarina A. Piha‐Paul, Chieh Tseng, Cheuk Hong Leung, (unknown), Daniel D. Karp, Vivek Subbiah, David S. Hong, Siqing Fu, Aung Naing, Jordi Rodón, Milind Javle, Jaffer A. Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric‐Bernstam	1
2	A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. 2024 ·Journal of Clinical Oncology ·Thatcher Heumann, Mark Yarchoan, (unknown), Jiayun Lu, Daneng Li, Paul R. Kunk, Renuka Iyer, Farshid Dayyani, Lionel Aurelien Kankeu Fonkoua, (unknown), Olumide B. Gbolahan, Milind Javle, S. Lindsey Davis, Vaia Florou, James R. Wright, Elad Sharon, Hao Wang, Gregory B. Lesinski, Nilofer S. Azad	3
3	PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Sunyoung S. Lee, Khaldoun Almhanna, (unknown), Shubham Pant, J. Kuban, Aaron Maxwell, (unknown), (unknown), (unknown), Bryan F. Cox, Richard D. Carvajal, Ruth A. White, Joshua Weintraub, (unknown), James Hart, Robert Knight, Steven C. Katz, Milind Javle	3
4	Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing 2023 ·SHILAP Revista de lepidopterología ·(unknown), Molly S. Daniels, (unknown), Ecaterina E. Dumbrava, Ying Yuan, Keyur P. Patel, (unknown), (unknown), Chetna Wathoo, (unknown), (unknown), Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodón, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric‐Bernstam	1
5	1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC) 2023 ·Annals of Oncology ·(unknown), (unknown), (unknown), Matthew H. G. Katz, Naruhiko Ikoma, (unknown), Michael J. Overman, Shubham Pant, (unknown), Robert A. Wolff, Milind Javle, Cullen M. Taniguchi, Ethan B. Ludmir, Prajnan Das, Albert C. Koong, Omar I. Vivar, (unknown), Eric P. Tamm, Manoop S. Bhutani, Eugene J. Koay	2
6	SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial 2023 ·Annals of Oncology ·Juan W. Valle, Ghassan K. Abou‐Alfa, Robin Kate Kelley, Maeve A. Lowery, Rachna T. Shroff, Yunyi Bian, Gaëlle Saint‐Hilary, Hui Liu, Zhongzhao Teng, Hua Zhang, Camelia Gliser, Arndt Vogel, Milind Javle	0
7	Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis 2023 ·The Oncologist ·(unknown), Brian De, Sunyoung S. Lee, Joseph Abi Jaoude, Jean‐Nicolas Vauthey, Ching‐Wei D. Tzeng, Hop S. Tran Cao, Kalman A. Katlowitz, Jacob Mandel, Thomas H. Beckham, Bruce D. Minsky, Grace L. Smith, Emma B. Holliday, Albert C. Koong, Prajnan Das, Cullen M. Taniguchi, Milind Javle, Eugene J. Koay, Ethan B. Ludmir	2
8	Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Rikita Hatia, (unknown), Ernest T. Hawk, (unknown), (unknown), Ahmed Shalaby, Ahmed Abdelhakeem, Reham Abdel‐Wahab, Ping Chang, Asif Rashid, Prasun K. Jalal, Christopher I. Amos, Younghun Han, Tannaz Armaghany, Rachna T. Shroff, Donghui Li, Milind Javle, Manal M. Hassan	2
9	A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors 2023 ·Cancer ·Filip Jankú, Milind Javle, Shiraj Sen, Shubham Pant, (unknown), Vivek Subbiah, (unknown), David Wages, Catherine Wheeler, (unknown), Kazunori Saeki, Ruth Ann Subach, Timothy Madden, (unknown), Mary Johansen, K.Y. Cheung, Gerald S. Falchook	1
10	BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study 2023 ·npj Precision Oncology ·Blessie Elizabeth Nelson, Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing, Sarina A. Piha‐Paul, Siqing Fu, Apostolia M. Tsimberidou, Maria E. Cabanillas, Naifa L. Busaidy, Milind Javle, Lauren A. Byers, John V. Heymach, Funda Meric‐Bernstam, Vivek Subbiah	16
11	Comparative Genomic Analysis and Clinical Outcomes of BRAF -mutated Advanced Biliary Tract Cancers 2023 ·Clinical Cancer Research ·(unknown), Federico Nichetti, (unknown), Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Caterina Vivaldi, Lorenza Rimassa, Filippo de Braud, Mario Domenico Rizzato, Dean C. Pavlick, (unknown), (unknown), Radwa Sharaf, Ethan Sokol, Jordi Rodón, Jeffrey S. Ross, Milind Javle, Monica Niger	8
12	Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy 2022 ·Clinical Cancer Research ·Sunyoung Lee, Rachna T. Shroff, Shalini Makawita, Lianchun Xiao, (unknown), Priya Bhosale, (unknown), Ahmed Shalaby, Kanwal Raghav, Shubham Pant, Robert A. Wolff, Milind Javle	19
13	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States 2022 ·Cancer ·Brian De, Hop S. Tran Cao, Jean‐Nicolas Vauthey, (unknown), Kelsey L. Corrigan, Kanwal Raghav, Sunyoung S. Lee, Ching‐Wei D. Tzeng, Bruce D. Minsky, Grace L. Smith, Emma B. Holliday, Cullen M. Taniguchi, Albert C. Koong, Prajnan Das, Milind Javle, Ethan B. Ludmir, Eugene J. Koay	5
14	Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study breakdown → 2021 ·Cancer Discovery ·Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal	171
15	Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp) 2021 ·ESMO Open ·Milind Javle, Do‐Youn Oh, Masafumi Ikeda, Wei Peng Yong, (unknown), Bertil Lindmark, (unknown), (unknown)	24
16	Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial 2020 ·Journal of Pain and Symptom Management ·David Hui, (unknown), (unknown), Diane Liu, (unknown), Ahmed O. Kaseb, Milind Javle, Michael J. Overman, Sriram Yennurajalingam, Colleen M. Gallagher, Éduardo Bruera	1
17	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer 2019 ·Clinical Cancer Research ·(unknown), Kenneth R. Hess, Filip Jankú, Nora Sánchez, Kenna Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric‐Bernstam	40
18	Genetic landscape of gallbladder cancer: Global overview 2018 ·Mutation Research/Reviews in Mutation Research ·Ravi Mehrotra, Sonam Tulsyan, Showket Hussain, Balraj Mittal, Sundeep Singh Saluja, Sandeep Singh, Pranay Tanwar, Asiya Khan, Milind Javle, Manal M. Hassan, Shubham Pant, Xabier de Aretxabala, Bhawna Sirohi, Preetha Rajaraman, Tanvir Kaur, G.K. Rath	37
19	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma 2018 ·Cancer Medicine ·Dalia Elganainy, Emma B. Holliday, Cullen M. Taniguchi, Grace L. Smith, Rachna T. Shroff, Milind Javle, Kanwal Raghav, Ahmed O. Kaseb, Thomas A. Aloia, Jean‐Nicolas Vauthey, Ching‐Wei D. Tzeng, Joseph M. Herman, Albert C. Koong, Sunil Krishnan, Bruce D. Minsky, Christopher H. Crane, Prajnan Das, Eugene J. Koay	16
20	Risk Factors for Gastrointestinal Bleeding in Patients Treated with Radiation Therapy for Intrahepatic Cholangiocarcinoma 2011 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Christopher H. Crane, Milind Javle, Ahmed O. Kaseb, Waqar Haque, Marc E. Delclos, (unknown), Sam Beddar, Tina M. Briere, Prajnan Das	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact